celastrol has been researched along with lapatinib in 1 studies
| Studies (celastrol) | Trials (celastrol) | Recent Studies (post-2010) (celastrol) | Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) |
|---|---|---|---|---|---|
| 885 | 1 | 741 | 1,919 | 305 | 1,442 |
| Protein | Taxonomy | celastrol (IC50) | lapatinib (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 7.375 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0827 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0537 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 8.5 | |
| D(1A) dopamine receptor | Sus scrofa (pig) | 0.06 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.1659 | |
| Alpha-1A adrenergic receptor | Sus scrofa (pig) | 0.06 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 3.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bailey, TA; Band, H; Band, V; Clubb, RJ; Duan, L; Natarajan, A; Nyong, AM; Ortega-Cava, C; Raja, SM; Reddi, AL; Williams, SH; Zhao, X | 1 |
1 other study(ies) available for celastrol and lapatinib
| Article | Year |
|---|---|
Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Female; HSP90 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Lapatinib; Mice; Mice, SCID; Pentacyclic Triterpenes; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Triterpenes; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |